CNBC October 24, 2024
Key Points
– Novo Nordisk’s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, according to a new analysis of electronic health records.
– The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.
– Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients compared with seven other diabetes medications.
Novo Nordisk‘s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday.
Semaglutide, the active ingredient in Ozempic, was associated with a 40%...
Today's Sponsors
Today's Sponsor